<DOC>
	<DOC>NCT02918318</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of fixed dosed intranasal esketamine compared to intranasal placebo, as an add-on to an oral antidepressant in Japanese participants with treatment-resistant depression (TRD), in improving depressive symptoms.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
	<criteria>At the start of the screening phase, participant must meet the Diagnostic and Statistical Manual of Mental Disorders (DSM5) diagnostic criteria for recurrent major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Mini International Neuropsychiatric Interview (MINI) The participant's current major depressive episode, depression symptom severity (MADRS total score greater than or equal to [&gt;=] 28 required), and antidepressant treatment response in the current depressive episode, must be confirmed using the SAFER interview Participant must be medically stable on the basis of clinical laboratory tests, physical examination, medical history, vital signs (including blood pressure), pulse oximetry, and 12lead electrocardiogram (ECG) performed in the screening phase A woman of childbearing potential must have a negative highly sensitive serum Beta (β) human chorionic gonadotropin [βhCG] test at the start of the screening phase and a negative urine pregnancy test must be obtained before the first dose of study drug on Day 1 of the doubleblind induction phase prior to randomization Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for participant participating in clinical studies Participant has received vagal nerve stimulation or has received deep brain stimulation in the current episode of depression Participant previously received esketamine or ketamine as treatment for their MDD Participant has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 6 months prior to the start of the screening phase Participant has a history of moderate or severe substance or alcohol use disorder according to DSM5 criteria, except nicotine or caffeine, within 6 months before the start of the screening phase Participant has a current or past history of seizure disorder (uncomplicated childhood febrile seizures with no sequelae are not exclusionary)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>